Patents by Inventor Qiuya Huang

Qiuya Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors
    Publication number: 20180201622
    Abstract: A series of fused bicyclic heteroaromatic derivatives of formula (IA) or (IB), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase III? (PI4KIII?) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Application
    Filed: March 16, 2018
    Publication date: July 19, 2018
    Inventors: Daniel James Ford, Qiuya Huang, Judi Charlotte Neuss, James Thomas Reuberson, Bart Vanderhoydonck
  • Fused bicyclic heteroaromatic derivatives as kinase inhibitors
    Patent number: 10000497
    Abstract: A series of fused bicyclic heteroaromatic derivatives of formula (I), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase III? (PI4KIII?) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: June 19, 2018
    Assignees: UCB BIOPHARMA SPRL, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D
    Inventors: Helen Tracey Horsley, Qiuya Huang, Judi Charlotte Neuss, James Thomas Reuberson, Bart Vanderhoydonck
  • Fused bicyclic heteroaromatic derivatives as kinase inhibitors
    Patent number: 9969748
    Abstract: A series of fused bicyclic heteroaromatic derivatives of formula (IA) or (IB), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase III? (PI4KIII?) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: May 15, 2018
    Assignees: UCB Biopharma SPRL, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Daniel James Ford, Qiuya Huang, Judi Charlotte Neuss, James Thomas Reuberson, Bart Vanderhoydonck
  • Therapeutically active pyrazolo-pyrimidine derivatives
    Patent number: 9714248
    Abstract: A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: July 25, 2017
    Inventors: Daniel James Ford, Richard Jeremy Franklin, Anant Ramrao Ghawalkar, Helen Tracey Horsley, Qiuya Huang, James Thomas Reuberson, Bart Vanderhoydonck
  • Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors
    Publication number: 20170129905
    Abstract: A series of fused bicyclic heteroaromatic derivatives of formula (IA) or (IB), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase III? (PI4KIII?) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Application
    Filed: June 11, 2015
    Publication date: May 11, 2017
    Inventors: Daniel James Ford, Qiuya Huang, Judi Charlotte Neuss, James Thomas Reuberson, Bart Vanderhoydonck
  • Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors
    Publication number: 20170121337
    Abstract: A series of fused bicyclic heteroaromatic derivatives of formula (I), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase III? (PI4KIII?) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Application
    Filed: June 11, 2015
    Publication date: May 4, 2017
    Inventors: Helen Tracey Horsley, Qiuya Huang, Judi Charlotte Neuss, James Thomas Reuberson, Bart Vanderhoydonck
  • Therapeutically Active Pyrazolo-Pyrimidine Derivatives
    Publication number: 20160194329
    Abstract: A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Application
    Filed: December 20, 2013
    Publication date: July 7, 2016
    Inventors: Daniel James Ford, Richard Jeremy Franklin, Anant Ramrao Ghawalkar, Helen Tracey Horsley, Qiuya Huang, James Thomas Reuberson, Bart Vanderhoydonck
  • Autoimmune and inflammatory disorder therapy
    Patent number: 9301961
    Abstract: Compounds that bind to phosphatidylinositol-4-kinase III? (PI4KIII?) and inhibit the binding of PI4KIII? to its substrate and/or inhibit PI4KIII? activity may be used in the treatment and/or prevention of an autoimmune or inflammatory disorder, or organ or cell transplant rejection. A new assay for identifying compounds for use in treating and/or preventing those pathological conditions, which comprises measuring the inhibition of PI4KIII? activity, is also disclosed.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: April 5, 2016
    Assignee: Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Jean Herman, Thierry Louat, Qiuya Huang, Bart Vanderhoydonck, Mark Waer, Piet Herdewijn
  • Therapeutically active fused pyrimidine derivatives
    Patent number: 9227984
    Abstract: A series of monocyclic or bicyclic diamine-substituted thieno[2,3-d]pyrimidine and isothiazolo[5,4-d]pyrimidine derivatives are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.
    Type: Grant
    Filed: August 15, 2012
    Date of Patent: January 5, 2016
    Assignees: UCB Pharma S.A., Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Daniel Christopher Brookings, Daniel James Ford, Anant Ramrao Ghawalkar, Jean Herman, Qiuya Huang, Claire Louise Kulisa, Thierry Louat, Judi Charlotte Neuss, James Thomas Reuberson, Bart Vanderhoydonck
  • Therapeutically Active Fused Pyrimidine Derivatives
    Publication number: 20140309222
    Abstract: A series of monocyclic or bicyclic diamine-substituted thieno[2,3-d]pyrimidine and isothiazolo[5,4-d]pyrimidine derivatives are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.
    Type: Application
    Filed: August 15, 2012
    Publication date: October 16, 2014
    Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D, UCB PHARMA S.A.
    Inventors: Daniel Christopher Brookings, Daniel James Ford, Anant Ramrao Ghawalkar, Jean Herman, Qiuya Huang, Claire Louise Kulisa, Thierry Louat, Judi Charlotte Neuss, James Thomas Reuberson, Bart Vanderhoydonck
  • Autoimmune and Inflammatory Disorder Therapy
    Publication number: 20140294870
    Abstract: Compounds that bind to phosphatidylinositol-4-kinase III? (PI4KIII?) and inhibit the binding of PI4KIII? to its substrate and/or inhibit PI4KIII? activity may be used in the treatment and/or prevention of an autoimmune or inflammatory disorder, or organ or cell transplant rejection. A new assay for identifying compounds for use in treating and/or preventing those pathological conditions, which comprises measuring the inhibition of PI4KIII? activity, is also disclosed.
    Type: Application
    Filed: September 7, 2012
    Publication date: October 2, 2014
    Applicant: KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D
    Inventors: Jean Herman, Thierry Louat, Qiuya Huang, Bart Vanderhoydonck, Mark Waer, Piet Herdewijn
  • Substituted sulfoxide compounds, methods for preparing the same and use thereof
    Patent number: 8017784
    Abstract: Disclosed are an optically pure compound having formula I, its pharmaceutically acceptable salt and its pharmaceutically acceptable solvate, and a use thereof in manufacturing medicaments and pharmaceutical compositions. A process for preparing the compound defined therein is also provided.
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: September 13, 2011
    Assignee: Livzon Pharmaceutical Group, Inc.
    Inventors: Jingen Deng, Qin Yang, Yongle Chen, Jin Zhu, Qiwei Wang, Qiuya Huang, Xuemei Hou
  • SUBSTITUTED SULFOXIDE COMPOUNDS, METHODS FOR PREPARING THE SAME AND USE THEREOF
    Publication number: 20080234487
    Abstract: Disclosed are an optically pure compound having formula I, its pharmaceutically acceptable salt and its pharmaceutically acceptable solvate, and a use thereof in manufacturing medicaments and pharmaceutical compositions. A process for preparing the compound defined therein is also provided.
    Type: Application
    Filed: May 23, 2008
    Publication date: September 25, 2008
    Inventors: Jingen DENG, Qin YANG, Yongle CHEN, Jin ZHU, Qiwei WANG, Qiuya HUANG, Xuemei HOU
  • Substituted sulfoxide compounds, methods for preparing the same and use thereof
    Publication number: 20060217423
    Abstract: Disclosed are an optically pure compound having formula I, its pharmaceutically acceptable salt and its pharmaceutically acceptable solvate, and a use thereof in manufacturing medicaments and pharmaceutical compositions. A process for preparing the compound defined therein is also provided.
    Type: Application
    Filed: March 24, 2006
    Publication date: September 28, 2006
    Inventors: Jingen Deng, Qin Yang, Yongle Chen, Jin Zhu, Qiwei Wang, Qiuya Huang, Xuemei Hou
  • Therapeutically active pyrazolo-pyrimidine derivatives
    Patent number: RE48622
    Abstract: A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: July 6, 2021
    Assignees: UCB Biopharma SRL, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Daniel James Ford, Richard Jeremy Franklin, Anant Ramrao Ghawalkar, Helen Tracey Horsley, Qiuya Huang, James Thomas Reuberson, Bart Vanderhoydonck